CN110214136A - 作为malt1抑制剂的吡唑衍生物 - Google Patents

作为malt1抑制剂的吡唑衍生物 Download PDF

Info

Publication number
CN110214136A
CN110214136A CN201780079706.3A CN201780079706A CN110214136A CN 110214136 A CN110214136 A CN 110214136A CN 201780079706 A CN201780079706 A CN 201780079706A CN 110214136 A CN110214136 A CN 110214136A
Authority
CN
China
Prior art keywords
pyridin
trifluoromethyl
pyrazole
carboxamide
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780079706.3A
Other languages
English (en)
Chinese (zh)
Inventor
T.鲁
B.D.艾利森
J.K.巴尔贝
P.J.康诺利
M.D.卡明斯
G.狄尔斯
J.P.爱德华兹
K.D.克罗伊特
U.菲利帕
F.沈
J.W.J.F.图林
T.吴
D.J-C.贝特洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN110214136A publication Critical patent/CN110214136A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780079706.3A 2016-12-21 2017-12-20 作为malt1抑制剂的吡唑衍生物 Pending CN110214136A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437384P 2016-12-21 2016-12-21
US62/437,384 2016-12-21
PCT/US2017/067516 WO2018119036A1 (en) 2016-12-21 2017-12-20 Pyrazole derivatives as malt1 inhibitors

Publications (1)

Publication Number Publication Date
CN110214136A true CN110214136A (zh) 2019-09-06

Family

ID=61628454

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780079706.3A Pending CN110214136A (zh) 2016-12-21 2017-12-20 作为malt1抑制剂的吡唑衍生物

Country Status (23)

Country Link
US (2) US10954214B2 (https=)
EP (1) EP3558969B1 (https=)
JP (1) JP7138641B2 (https=)
KR (1) KR102583317B1 (https=)
CN (1) CN110214136A (https=)
AR (1) AR110421A1 (https=)
AU (2) AU2017382185C1 (https=)
BR (1) BR112019012355A2 (https=)
CA (1) CA3048027A1 (https=)
CL (1) CL2019001709A1 (https=)
CO (1) CO2019006622A2 (https=)
EA (1) EA201991503A1 (https=)
ES (1) ES2992411T3 (https=)
IL (1) IL267343B2 (https=)
MA (1) MA47125A (https=)
MX (2) MX392673B (https=)
PE (1) PE20191755A1 (https=)
PH (1) PH12019501212A1 (https=)
TN (1) TN2019000192A1 (https=)
TW (1) TWI795381B (https=)
UA (1) UA127920C2 (https=)
UY (1) UY37537A (https=)
WO (1) WO2018119036A1 (https=)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113912511A (zh) * 2021-11-29 2022-01-11 广东广康生化科技股份有限公司 一种联苯肼酯中间体的合成方法
CN114981453A (zh) * 2019-11-22 2022-08-30 詹森药业有限公司 用于评估malt1抑制剂的功效的nf-kb调节的基因表达测定
CN115210567A (zh) * 2019-11-22 2022-10-18 詹森药业有限公司 使用nf-kb转位测定来评估malt1抑制剂的功效的方法
WO2022262855A1 (zh) * 2021-06-18 2022-12-22 上海拓界生物医药科技有限公司 一种malt1抑制剂及其制备方法和用途
WO2023279986A1 (zh) * 2021-07-05 2023-01-12 贝达药业股份有限公司 六元芳基或杂芳基酰胺类化合物及其组合物和用途
WO2023125877A1 (zh) * 2021-12-30 2023-07-06 上海翰森生物医药科技有限公司 三并环类衍生物抑制剂、其制备方法和应用
CN116528857A (zh) * 2020-11-23 2023-08-01 艾克斯赛安西娅人工智能有限公司 Malt-1调节剂
CN116916924A (zh) * 2020-10-16 2023-10-20 稀有生物科学股份有限公司 Malt1调节剂及其用途
CN117715898A (zh) * 2021-07-05 2024-03-15 贝达药业股份有限公司 六元芳基或杂芳基酰胺类化合物及其组合物和用途
WO2024125628A1 (zh) * 2022-12-16 2024-06-20 江苏恒瑞医药股份有限公司 一种Malt 1抑制剂的磷酸酯前药
WO2025002333A1 (zh) * 2023-06-29 2025-01-02 上海翰森生物医药科技有限公司 一种三并环类衍生物抑制剂的晶型及其制备方法
WO2025002340A1 (zh) * 2023-06-29 2025-01-02 上海翰森生物医药科技有限公司 三并环类抑制剂与抗癌剂在制备抗肿瘤药物中的联合应用

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
JP7101678B2 (ja) 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
AU2018395291A1 (en) 2017-12-28 2020-07-30 The General Hospital Corporation Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
SMT202500157T1 (it) 2018-03-30 2025-05-12 Incyte Corp Composti eterociclici come immunomodulatori
HUE061503T2 (hu) 2018-05-11 2023-07-28 Incyte Corp Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
EP3810609B1 (en) * 2018-06-18 2024-06-12 Janssen Pharmaceutica NV Pyrazole derivatives as malt1 inhibitors
AU2019289222B2 (en) 2018-06-18 2023-07-13 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
TW202045008A (zh) * 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途
US20220175760A1 (en) * 2019-02-22 2022-06-09 Janssen Pharmaceutica Nv Pharmaceutical formulations
US12269813B2 (en) * 2019-02-22 2025-04-08 Janssen Pharmaceutica Nv Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
JP7665593B2 (ja) 2019-08-09 2025-04-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
PE20221038A1 (es) 2019-09-30 2022-06-17 Incyte Corp Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores
WO2021080015A1 (en) * 2019-10-24 2021-04-29 Ono Pharmaceutical Co., Ltd. Modulators of trek (twik related k+ channels) channel function
EP4051679B1 (en) 2019-10-30 2025-08-06 Biogen MA Inc. Condensed pyridazine or pyrimidine as btk inhibitors
CA3160131A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
WO2021138298A1 (en) * 2019-12-30 2021-07-08 Rheos Medicines, Inc. Malt1 modulators and uses thereof
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
JP2023538099A (ja) 2020-08-21 2023-09-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤と、ポリエチレングリコールの脂肪酸との混合物と、を含む、医薬製剤
TW202227067A (zh) * 2020-08-21 2022-07-16 比利時商健生藥品公司 Ｍａｌｔ１抑制劑之無定形形式及其配製物
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
CR20230230A (es) 2020-11-06 2023-07-27 Incyte Corp Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
WO2022101676A1 (en) * 2020-11-12 2022-05-19 Monopteros Therapeutics,Inc. Materials and methods of treating cancer
EP4288417A4 (en) * 2021-02-04 2025-04-09 Aurigene Oncology Limited Substituted pyrazolyl compounds as malt-1 inhibitors
BR112023017648A2 (pt) * 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk
BR112023017689A2 (pt) 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida)
MX2024001840A (es) 2021-08-09 2024-02-28 Janssen Pharmaceutica Nv Composiciones para usar en el tratamiento de neoplasias de celulas b.
EP4473966A4 (en) 2022-02-02 2026-01-21 Ono Pharmaceutical Co CANCER TREATMENT AGENT COMPRISING A MALT1 INHIBITOR DRUG AS THE ACTIVE INGREDIENT
EP4472734A1 (en) * 2022-02-03 2024-12-11 C4X Discovery Limited Heterocyclic derivatives as malt1 inhibitors
TW202430031A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
TW202430514A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
WO2024115512A1 (en) 2022-11-30 2024-06-06 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline derivatives
WO2025069270A1 (ja) * 2023-09-27 2025-04-03 日本新薬株式会社 アザインドール化合物及び医薬
WO2025073968A1 (en) 2023-10-06 2025-04-10 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor
WO2025114167A1 (en) 2023-11-28 2025-06-05 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025174889A1 (en) * 2024-02-13 2025-08-21 Board Of Regents, The University Of Texas System Malt1 and btk dual inhibitors
WO2025191053A1 (en) 2024-03-14 2025-09-18 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025210095A1 (en) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline compounds
WO2025210096A1 (en) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Fungicidal compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1275979A (zh) * 1997-10-16 2000-12-06 美国辉瑞有限公司 用作尿激酶抑制剂的异喹啉化合物
WO2004098518A2 (en) * 2003-05-01 2004-11-18 Bristol-Myers Squibb Company Pyrazole-amide compounds useful as kinase inhibitors
CN101321748A (zh) * 2005-12-08 2008-12-10 欧加农股份有限公司 异喹啉衍生物

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
WO2003037274A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
WO2004098515A2 (en) * 2003-04-30 2004-11-18 Agensys, Inc. Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
EP1847531A4 (en) 2005-02-09 2009-04-22 Takeda Pharmaceutical PYRAZOLE DERIVATIVE
CN100526430C (zh) 2005-10-19 2009-08-12 中国石油化工股份有限公司 一种生产清洁汽油的方法
JP2009533327A (ja) 2006-03-22 2009-09-17 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患を処置するためのｃ−ＭＥＴキナーゼ阻害剤
US20090253673A1 (en) 2006-07-12 2009-10-08 Min Ge Substituted Pyrazoles as Ghrelin Receptor Antagonists
CN101583601B (zh) 2007-01-17 2013-06-05 香港科技大学 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物
WO2008110196A1 (en) 2007-03-09 2008-09-18 High Point Pharmaceuticals, Llc Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
CN101366715A (zh) 2007-08-15 2009-02-18 上海医药工业研究院 一种雷帕霉素组合物及其制备方法
US8309523B2 (en) 2007-11-21 2012-11-13 Vib Vzw Inhibitors of MALT1 proteolytic activity and uses thereof
KR101364869B1 (ko) 2008-09-24 2014-02-21 바스프 에스이 무척추　해충을　방제하기　위한　피라졸　화합물
WO2010039039A1 (en) 2008-10-03 2010-04-08 Clavis Pharma Asa Oral formulations of gemcitabine derivatives
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
DE102009003954A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2011036885A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
ES2539379T3 (es) 2010-06-22 2015-06-30 Basf Se Procedimiento de preparación de 4-hidroxipiridinas
US20130109682A1 (en) 2010-07-06 2013-05-02 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
TW201236685A (en) 2010-11-11 2012-09-16 Daiichi Sankyo Co Ltd New pyrazole amide derivatives
JP6231085B2 (ja) 2012-05-31 2017-11-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト アミノキナゾリン誘導体及びピリドピリミジン誘導体
US20150225373A1 (en) 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
EA201590916A1 (ru) 2012-11-09 2016-02-29 Корнэлл Юниверсити Низкомолекулярные ингибиторы malt1
WO2014086478A1 (en) 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
AR094412A1 (es) 2013-01-10 2015-07-29 Gruenenthal Gmbh Carboxamidas basadas en pirazolilo i
JP2015096499A (ja) * 2013-10-11 2015-05-21 田辺三菱製薬株式会社 医薬組成物
SG11201607895PA (en) * 2014-05-28 2016-12-29 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
US20150361504A1 (en) 2014-06-13 2015-12-17 Pharmacyclics Llc Biomarker for predicting response of cll to treatment with a btk inhibitor
WO2016005994A2 (en) 2014-07-06 2016-01-14 Gattefosse India Pvt. Ltd. Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires
AU2015300966A1 (en) 2014-08-08 2017-02-16 Janssen Pharmaceutica Nv Bruton's tyrosine kinase inhibitor combinations and uses thereof
WO2016037578A1 (en) 2014-09-10 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Novel compounds as rearranged during transfection (ret) inhibitors
HK1244427A1 (zh) 2014-12-06 2018-08-10 Intra-Cellular Therapies, Inc. 有机化合物
WO2016209688A1 (en) 2015-06-24 2016-12-29 University Of Florida Research Foundation, Incorporated Compositions for the treatment of cancer and uses thereof
PT3371190T (pt) 2015-11-06 2022-07-08 Incyte Corp Compostos heterocíclicos como inibidores de pi3k-gamma
AU2016352813B2 (en) * 2015-11-13 2019-09-19 Novartis Ag Novel pyrazolo pyrimidine derivatives
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
US10882841B2 (en) 2016-03-01 2021-01-05 University Of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
PE20190656A1 (es) 2016-07-29 2019-05-08 Lupin Ltd Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
JOP20190148A1 (ar) 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
AU2017383236B2 (en) 2016-12-21 2022-02-10 Acerta Pharma B.V. Imidazopyrazine inhibitors of Bruton's tyrosine kinase
JOP20190141A1 (ar) 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
MX2019007161A (es) 2016-12-21 2020-02-12 Mereo Biopharma 3 Ltd Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
US20200009135A1 (en) 2017-02-01 2020-01-09 Medivir Ab Therapeutic applications of malt1 inhibitors
WO2018165385A1 (en) 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
AU2018395291A1 (en) 2017-12-28 2020-07-30 The General Hospital Corporation Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
EP3756268A1 (de) 2018-02-23 2020-12-30 Industrieanlagen-Betriebsgesellschaft mbH Vorrichtung zum erzeugen eines magnetfelds, insbesondere für ein induktives ladesystem, und primäreinrichtung eines induktiven ladesystems zum dynamischen aufladen von fahrzeugen
EP3810609B1 (en) 2018-06-18 2024-06-12 Janssen Pharmaceutica NV Pyrazole derivatives as malt1 inhibitors
AU2019289222B2 (en) 2018-06-18 2023-07-13 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
US12269813B2 (en) 2019-02-22 2025-04-08 Janssen Pharmaceutica Nv Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate
US20220175760A1 (en) 2019-02-22 2022-06-09 Janssen Pharmaceutica Nv Pharmaceutical formulations
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
KR20220116460A (ko) 2019-11-22 2022-08-23 얀센 파마슈티카 엔.브이. NF-kB 전좌 분석을 사용하여 MALT1 억제제의 효능을 평가하기 위한 방법
US20210155990A1 (en) 2019-11-22 2021-05-27 Janssen Pharmaceutica Nv Nf-kb regulated gene expression assay for assessing efficacy of malt1 inhibitors
WO2021138298A1 (en) 2019-12-30 2021-07-08 Rheos Medicines, Inc. Malt1 modulators and uses thereof
JP2023538099A (ja) 2020-08-21 2023-09-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤と、ポリエチレングリコールの脂肪酸との混合物と、を含む、医薬製剤
TW202227067A (zh) 2020-08-21 2022-07-16 比利時商健生藥品公司 Ｍａｌｔ１抑制劑之無定形形式及其配製物
BR112023017689A2 (pt) 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida)
BR112023017648A2 (pt) 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1275979A (zh) * 1997-10-16 2000-12-06 美国辉瑞有限公司 用作尿激酶抑制剂的异喹啉化合物
WO2004098518A2 (en) * 2003-05-01 2004-11-18 Bristol-Myers Squibb Company Pyrazole-amide compounds useful as kinase inhibitors
CN1816529A (zh) * 2003-05-01 2006-08-09 布里斯托尔-迈尔斯.斯奎布公司 用作激酶抑制剂的芳基取代的吡唑－酰胺化合物
CN101321748A (zh) * 2005-12-08 2008-12-10 欧加农股份有限公司 异喹啉衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHE BOLDRON 等: "N-[6-(4-Butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a Novel Intravenous and Oral, Reversible, and Directly Acting P2Y12 Antagonist", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
孙晓杰 等: "《肿瘤分子诊断与靶向治疗》", 31 July 2009 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114981453A (zh) * 2019-11-22 2022-08-30 詹森药业有限公司 用于评估malt1抑制剂的功效的nf-kb调节的基因表达测定
CN115210567A (zh) * 2019-11-22 2022-10-18 詹森药业有限公司 使用nf-kb转位测定来评估malt1抑制剂的功效的方法
CN116916924B (zh) * 2020-10-16 2026-02-27 稀有生物科学股份有限公司 Malt1调节剂及其用途
CN116916924A (zh) * 2020-10-16 2023-10-20 稀有生物科学股份有限公司 Malt1调节剂及其用途
CN116528857A (zh) * 2020-11-23 2023-08-01 艾克斯赛安西娅人工智能有限公司 Malt-1调节剂
WO2022262855A1 (zh) * 2021-06-18 2022-12-22 上海拓界生物医药科技有限公司 一种malt1抑制剂及其制备方法和用途
CN117120427A (zh) * 2021-06-18 2023-11-24 上海拓界生物医药科技有限公司 一种malt1抑制剂及其制备方法和用途
WO2023279986A1 (zh) * 2021-07-05 2023-01-12 贝达药业股份有限公司 六元芳基或杂芳基酰胺类化合物及其组合物和用途
CN117715898A (zh) * 2021-07-05 2024-03-15 贝达药业股份有限公司 六元芳基或杂芳基酰胺类化合物及其组合物和用途
CN113912511B (zh) * 2021-11-29 2024-02-13 广东广康生化科技股份有限公司 一种联苯肼酯中间体的合成方法
CN113912511A (zh) * 2021-11-29 2022-01-11 广东广康生化科技股份有限公司 一种联苯肼酯中间体的合成方法
WO2023125877A1 (zh) * 2021-12-30 2023-07-06 上海翰森生物医药科技有限公司 三并环类衍生物抑制剂、其制备方法和应用
WO2024125628A1 (zh) * 2022-12-16 2024-06-20 江苏恒瑞医药股份有限公司 一种Malt 1抑制剂的磷酸酯前药
WO2025002333A1 (zh) * 2023-06-29 2025-01-02 上海翰森生物医药科技有限公司 一种三并环类衍生物抑制剂的晶型及其制备方法
WO2025002340A1 (zh) * 2023-06-29 2025-01-02 上海翰森生物医药科技有限公司 三并环类抑制剂与抗癌剂在制备抗肿瘤药物中的联合应用

Also Published As

Publication number Publication date
JP7138641B2 (ja) 2022-09-16
AU2017382185C1 (en) 2022-08-11
KR20190093669A (ko) 2019-08-09
US12077521B2 (en) 2024-09-03
MX2022005827A (es) 2022-06-08
MX392673B (es) 2025-03-24
BR112019012355A2 (pt) 2019-11-26
CO2019006622A2 (es) 2019-06-28
IL267343B2 (en) 2023-06-01
AU2017382185A1 (en) 2019-06-13
ES2992411T3 (es) 2024-12-12
AU2022201352A1 (en) 2022-03-24
CA3048027A1 (en) 2018-06-28
CL2019001709A1 (es) 2019-10-04
AU2017382185B2 (en) 2021-12-02
KR102583317B1 (ko) 2023-09-27
EP3558969C0 (en) 2024-09-18
US20180170909A1 (en) 2018-06-21
US20220315557A1 (en) 2022-10-06
PH12019501212A1 (en) 2019-12-16
TWI795381B (zh) 2023-03-11
JP2020514267A (ja) 2020-05-21
AU2017382185C9 (en) 2022-08-04
US10954214B2 (en) 2021-03-23
UA127920C2 (uk) 2024-02-14
WO2018119036A1 (en) 2018-06-28
EP3558969B1 (en) 2024-09-18
IL267343A (en) 2019-08-29
UY37537A (es) 2018-06-29
TW201835067A (zh) 2018-10-01
AR110421A1 (es) 2019-03-27
EP3558969A1 (en) 2019-10-30
TN2019000192A1 (en) 2020-10-05
EA201991503A1 (ru) 2019-11-29
MX2019007540A (es) 2019-10-24
MA47125A (fr) 2021-04-28
PE20191755A1 (es) 2019-12-12

Similar Documents

Publication Publication Date Title
US12077521B2 (en) Pyrazole derivatives as MALT1 inhibitors
CN103582637B (zh) 酪氨酸激酶抑制剂
CN112585128B (zh) 作为malt1抑制剂的吡唑衍生物
JP2023538060A (ja) 二環化合物、それを含む組成物、及びそれらの使用
CN110036004A (zh) 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
CN120712252A (zh) 包含sos1抑制剂和抗癌药物的用于治疗癌症的药物组合物
KR20170040300A (ko) 2-(모르폴린-4-일)-l,7-나프티리딘
TWI822754B (zh) 作為crhr2拮抗劑之稠合環狀脲衍生物
CN114945571A (zh) 环状化合物及其使用方法
TW202404590A (zh) Ｅｇｆｒ抑制劑
CN114630822B (zh) 联芳基二氢乳清酸脱氢酶抑制剂
CN110191884A (zh) 取代的6-(1h-吡唑-1-基)嘧啶-4-胺衍生物及其用途
CN110818683A (zh) 2-吡啶取代脲结构小分子化合物及其合成和应用
HK40014620A (en) Pyrazole derivatives as malt1 inhibitors
EA045333B1 (ru) Производные пиразола в качестве ингибиторов malt1
OA19506A (en) Pyrazole derivatives as malt1 inhibitors.
OA20881A (en) Pyrazole derivatives as MALT1 inhibitors.
HK40040496A (en) Pyrazole derivatives as malt1 inhibitors
HK40012363A (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
HK1194381B (en) Inhibitors of bruton's tyrosine kinase
HK1210155B (zh) 含氮杂环化合物或其盐

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40014620

Country of ref document: HK